Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're right, he just employs them. As most CEOs do. I'm invested in the tech not the price; what about you?
Do your own DD: etc. etc. etc.
Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in Pharmacology and a B.Sc. in Toxicology from the University of Toronto.
Dr. Ainslie is Co-Director for the Centre for Heart, Lung and Vascular Health, Canada, Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia, Okanagan Campus. His research is directed to the integrated mechanisms, which regulate human cerebral blood flow in health and disease with specific areas of interest including fundamental mechanisms of cerebral blood flow regulation, influence of environmental stress on cerebrovascular function (with focus on normobaric and hypobaric hypoxia; in addition to temperature regulation and influence of different forms of sleep apnea on cerebrovascular function).
Dr. Carla Lema Tome is an industry consultant an Adjunct Assistant Professor of Neurobiology and Anatomy at Wake Forest University School of Medicine. She is widely published on topics including but not limited to cellular and molecular neuroscience, inflammation, neurodegeneration, and cancer biology. She has extensive experience in global medical and commercial strategy consulting with emphasis on integrated clinical development, asset and portfolio strategy, launch planning payer research and payer value communications. Her work supporting bioscience projects with high market potential includes development of forecast and valuation models, conducting strategic analyses of the competitive and market access environment, and developing integrated plans and innovative strategies to maximize asset value. Dr. Lema Tome earned her PhD in Neurobiology and Anatomy and her MBA from Wake Forest University. She also earned an MS in Biological Sciences, Marine Biology, from the Florida Institute of Technology.
Also, just a reminder that this company can be very successful in the weed space, even with so much of the boards focus being on nicotine delivery systems (and for good reason). Let's stay positive here.
“As the fastest growing edibles brand in Colorado, we believe a huge part of our consumer appeal is because of this fast-acting technology,” said Peter Barsoom, Nuka Enterprises CEO and Co-Founder. “We look forward to continuing to innovate alongside Lexaria, whose technology is the best in the industry.”
https://www.apnews.com/ACCESSWIRE/092d51fc321bfdc774dd34feea615ad9
Can't remember the last time the volume was below 10k after 1:30. Feeling like we either go full trend reversal here in the next few days or see an even steeper sudden drop to the low 0.70s. In the past few years though completely anemic volume has usually been a pre-cursor to large buying blocks and multiple day-over-day gains of +20%.
Price has been beyond frustrating but the strong foundations of their tech continue to be laid out, and I still have full confidence in the vision the company is pursuing. Looking forward to some of those 1906 bars coming to CA
Most of those stocks you listed are down nearly 50% from where they were 6 months ago
It's an interesting question for sure. I think long term that CBD/THC applications should be the biggest market, as most states with recreational use have limits on total amount allowed per edible (100 mg usually). That means that, theoretically, Lexaria licensee's could be selling edibles that adhere to the regulations, while increasing the effects of the same dosage by 50% or more. This means consumers are getting way more bang for their buck, especially if they are priced the same as current industry leaders (like kiva and kushy punch)
However, from a purely stock price standpoint, I think a nicotine deal would be massive. It would move the stock from a "weed play" to more of a biotech/pharma play, by proving that the tech can be applied across a broad spectrum. Furthermore, big tobacco has deep pockets. Phillip Morris alone is spending a LOT of money looking for healthier alternatives to cigarettes.
Finally, and in a similar vein to the nicotine application, a deal with a pharma industry company for NSAIDS could be huge. Reducing dosage while keeping effects would be a game changer, as NSAID use is really terrible for one's stomach lining and is hard for the body to process. This also accomplishes the same goal of establishing Lexaria as a true biotech play (think GW Pharma).
Just my two cents
Cool, thanks. I always appreciate your insight. I've been adding below 1.35 the past few weeks.
Best
Do you see it going much lower from here, or do you think the support line at $1.30 or so will continue to be the fluctuation point before it starts moving in the other direction again?
Seems to have been a pattern in the past 5 trading days: low volume days with a spurt of buying in the dying minutes equal to ~10-15% of daily volume. Could be someone accumulating and not wanting to miss the run that is brought on by a morning news release? (have to assume they think it'll come in the morning with this buying pattern). This has been the biggest one in awhile though, it's certainly interesting.
I've been getting those calm before the storm vibes the past few weeks, but I think we bounce around here for a little while longer.
Just a reminder that another conference starts tomorrow that Lexaria seems to be pretty majorly featured in. Maybe we'll get some coupled PRs, or at the very least some more eyes with more money.
On May 9-11 we are exhibiting in Booth 313 at the New Orleans MJBiz conference, if you're in the area we'd love for you to come by and introduce yourself! We’ll have plenty of staff available to answer your questions and provide you with greater insight into how our technology works. Lexaria has NEVER been busier than we are now and it will be awesome to share our latest developments with you.
As well, Lexaria is sponsoring the 2018 DOPE Magazine Golden Ticket after-party on the evening of Thursday May 10th. This will be the most-talked about event of the busy New Orleans week, Reach out to Dope Magazine for tickets soon before they are gone! Do you have your Golden Ticket?!
I honestly think it's a good thing. Edible cannabis/CBD is easily going to be a multi-billion dollar industry within a decade (if not sooner). Having companies competing to get to the top with innovative tech will, in my opinion, only bring more eyes to the sector. I definitely think there's enough space for multiple approaches and companies. It's early days, this only makes me more excited.
I believe when the low is a number it means Ouch! It's up to you to decide what's ouching though, Mr. T can't give away ALL his brilliant insight for free y'know.
Someone please correct me if I'm getting ahead of myself but... this is a BIG deal!! Particularly excited by
Nuka has been utilizing Lexaria’s technology within its award-winning 1906 brand chocolates for nearly two years, during which time 1906 entered the cannabis market; advanced from a start-up to Colorado’s number-three cannabis chocolate brand available in over 150 locations
Tomorrow could be interesting
Fair enough, I think it's a "in due time" sort of thing. I'd like to get well above $1 and stay there, but the reality is that the next year or two is gonna have some major gutchecks, what with the warrant schedule and all.
Hopefully we get some transdermal THC and/or nicotine news soon related to actually making products and not just the potential efficacy of the tech. That sort of thing would put lex squarely on the map. It's certainly been a tough month or so
Sounds very familiar. Point being that the whole sector is, for the most part, in the same boat
Those "big boys" have seen their share value drop from $3.40 in January to $1.18 today.
What do you think about the most recent warrant issue being above $1.80? Do you read into that as a sign by management of true confidence in the future of the company, or more as a way to try and push valuation in the market? I feel like that warrant issue coupled with the lack of any insider sales says they have things in the pipeline they truly believe in.
Thanks Knife, always appreciate the insight.
I think it's less so that most longs have left and more that there isn't a lot to talk about in either direction. I believe we've gotten to a point where the longs that are left have the necessary patience.
I sold about 20% of my total position over the last couple months, mostly for other opportunities with small windows. But I'm still holding the majority of my position here, purchase avg of 0.38, long and with confidence.
While the tech does require changing the manufacturing process of the drug in question, it's not changing the active biological compound within the final product. It's like liquigels verse capsules. Advil sels 200mg ibuprofen in both conformations, but one is a gel capsule with a liquid suspension of the active compound while the other is a hard pill with a sugar outside. Your body breaks them down at different rates, but the drug is the same.
I doubt they had to go through a full FDA approval process to make the switch to gel caps. Now I'm sure there are some safety related things they were obligated to show for the gel caps, but nothing as stringent as a new 510k submission.
The big question is whether the fact that the method of entry in to your blood stream may be different with Dehydratech compared to other versions of the compound would require a full FDA submission and approval process... I'm inclined to say that it won't be required since the active compound is the same as before. I could be wrong though
The stock has gone from under $0.50 to a steady base at ~$1.60 in less than 3 months. And the fact that they are now issuing warrants at @ $1.83 bodes very well for the future IMO. Let's all practice some patience, it'll get back to it soon enough. With the sentiment around here recently you'd think we had been on a multi-month downtrend or something
Just for CBDs though right? Any updates on the in vitro bioavailability for the other compounds where they see potential success of porting their lipid encapsulation technique(NSAID, Nicotine, etc)?
I'd love to get an update on any of those, I really think that's the diamond in the rough that a lot of people who only see this as an MJ play are completely missing.
If they can get their tech licensed to some of the bigger players in the MMJ industry (in CA, CO, etc) to generate some revenue in the immediate future, while also making strides in improving the efficacy and/or reducing the risk of some of the most used OTC pharmaceuticals in the world... We're talking serious serious potential here.
Just curious, does any one have any information on the study scope and design for the NRC beyond what's in this article?
"The Lexaria R&D will include many studies; and their objectives, design, and results will be reported as available. Lexaria’s patent applications name several groups of molecules, all of which will be studied within this budget:
Cannabinoids;
Vitamins;
NSAIDs; and,
Nicotine.
The R&D will include in vitro absorption studies utilizing Lexaria’s technology to examine improvements in absorption across human intestinal tissue."
http://www.lexariaenergy.com/news/lexaria-announces-million-dollar-research-and-development-program/
I work in molecular sciences so I'd be really curious to see the actual designs they have. I know this was only a couple months ago, but just was wondering if any one has seen any kind of update on it. Sounds very interesting/promising. If they can really increase the bioeffeciency of NSAIDs and reduce the deleterious effects on kidneys, thats a potentially $billion market
Business takes time. I get that you're either frustrated by the lack of news or more likely short and trying to create panic. I think it's pretty clear he's not a crook though, nothing he has done would suggest that. Yea the PR is non-existent right now, but once actual licensing deals are actually finalized, that represents a good time for a PR that isn't just fluff and will actually move the stock. Until then, take some blood pressure pills or something. Or sell and leave. Or keep shorting. But stop with the hysteria, it's just as annoying as the people who come in and say "We'll be at $3 within a month!!". Real businesses take time, especially in molecular science. If there's nothing solid by late September than I'll be more inclined to be frustrated right along with you, but let's give them some faith here.
Really great interview, thanks for posting. The whole thing is really interesting. I really like the way he speaks about it. I tried to annotate (roughly) the last five minutes or so the best I could
Q: As a potential investor when am I gonna see some growth and some monetizing on this tech?
Chris: Oh fair question. A year ago I would have had a harder time answering. In the last 6 months we’ve raised $3 mil. We have a healthy balance in our account, more $ coming in expected. For the first time in a long time we are fully funded for 2017 AND 2018. We just announced a $1mil R&D budget for 2017 and the first part of 2018. That too is gonna provide us with the foundation or framework to deliver on the licensing side of things.
A point I think I failed to make in the past is that we do have consumer products on the market, and they’re important because they are a good demonstration of our technology at work. But at our heart we are a technology licensing firm. And those relationships take some time, with corporate testing and fitting our recipes or tech into people’s existing recipes. So, I think in 2017 and early 2018, a pretty dramatic shift in our revenues. A shift upward. And since most of our revenues come from technology licensing. You have to understand our profit margins on those revenues are well north of 90%. A small amount of topline revenue growth will drive almost the equivalent amount of bottom-line earnings growth. So once our G&A is covered, which it is now from capital on hand, the bulk of that revenue, just like a software company, goes to the bottom line. So, I think we’re gonna see that shift later in 2017 and certainly in 2018.
I can’t go out much further than that, but I can tell you it’s been a real eye opener, even for me, to realize the stature of some of the companies that have approached us. Yea I mean I’m in my mid 50’s, I’ve been in the business world a long time, I’ve never experienced this in any company I’ve been in, that companies are so curious that they are calling us to set up meeting and see what we’re doing. So that doesn’t prove that anything major will happen with those companies but it’s certainly an indication of the level of their interest. And I can tell you we have quite a handful of PHDs on hand as consultants, or on the other side of those phone calls. The science works, its well understood and it works, the human physiology is well established.
I think what makes us really novel is that it’s just one of those really obvious things that no one ever really thought of before: it’s a marriage between biotech, physics, and food science.
We are planning and budgeting and fully funded for a tenfold increase in applied R&D this year. And that applied R&D is really gonna allow us to lever the science on to the bottom line. And I really think that by the end of 2017, we’re gonna have really piqued the interest of a lot of companies in a lot of sectors to want to partner with us to get our technology into their existing product lines and that will show dramatic revenue growth if we’re able to achieve that.
I was hoping to see some potential updates on Monday re: the expo. It's been so quiet around here recently, I was honestly expecting more of a PR push around 4/20, a date which frequently turns eyes toward this market. Not that I'm complaining, it seems like they're getting all of thier ducks in a row, but I just cant help to feel a little anxious.
Still waiting for that day that news drops on the THC patent in the US, or the THC patent in Canda, or that lot production on the joint venture has started, or who their LOIs are with in california, or that some of those LOIs have become deals, or, or, or. There's so much potential here and so much to be excited about, but it can be hard to stay patient, and a huge short position sitting on the market isn't making that any easier.
Do you think we see another major announcement before the end of May, or is that just too difficult to predict?
Lowest volume morning I've seen in awhile. Calm before the storm?
Over 100,000 shares traded right at the bell, and on the way up. Someone is loading up for that international patent news to hit the mainstream tomorrow
Rise of craft brewing. He helped the company out, saw big beer sales (molson, colors, bud, rolling rock, etc) losing out to craft brews. So he decided to cut his gains and go turn around a company in what he, and many others, see as the next big party industry. Vaping...
We'll see. I have faith in the 6 pillar plan IMO
Hey guys. Just wanna say I've been coming to this board almost daily for over a year. Got in right before the RS, day traded it for awhile. Split happened, got stuck, read about Dan and his successes at previous companies. Live in LA and have seen the rise of vaping in person. I'm holding long, and I've been burned before. But I truly believe in this company and the plans here AND the expansion of the industry. Not the business (which is a turnaround success story, mind you) but the industry!
Anyway. I agree with an above post that if PR and good Q1 ($17mi sales and/or more detail on the European/African expansion) doesn't come we're gonna start losing long term investors. Patience is key, and frustrating as all Fc. I really do see success here, it's too real of a business to not be a real business.
Disclosure: day-traded for profit before the split, up 3k. Currently 30k long at an average of 0.41 (we all know we're at LEAST hitting the 0.45 warrants)